Cell Biotech Co., Ltd. (KOSDAQ:049960)

Cell Biotech Statistics

Total Valuation

Cell Biotech has a market cap or net worth of KRW 90.00 billion. The enterprise value is 1.56 billion.

Market Cap	90.00B
Enterprise Value	1.56B

Important Dates

The next estimated earnings date is Wednesday, August 13, 2025.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

Cell Biotech has 6.84 million shares outstanding.

Current Share Class	6.84M
Shares Outstanding	6.84M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	34.49%
Owned by Institutions (%)	8.79%
Float	4.48M

Valuation Ratios

The trailing PE ratio is 6.46.

PE Ratio	6.46
Forward PE	n/a
PS Ratio	1.87
PB Ratio	0.73
P/TBV Ratio	0.74
P/FCF Ratio	5.45
P/OCF Ratio	5.12
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 0.14, with an EV/FCF ratio of 0.09.

EV / Earnings	0.11
EV / Sales	0.03
EV / EBITDA	0.14
EV / EBIT	0.22
EV / FCF	0.09

Financial Position

The company has a current ratio of 11.08, with a Debt / Equity ratio of 0.01.

Current Ratio	11.08
Quick Ratio	10.48
Debt / Equity	0.01
Debt / EBITDA	0.08
Debt / FCF	0.05
Interest Coverage	130.44

Financial Efficiency

Return on equity (ROE) is 11.85% and return on invested capital (ROIC) is 3.73%.

Return on Equity (ROE)	11.85%
Return on Assets (ROA)	3.50%
Return on Invested Capital (ROIC)	3.73%
Return on Capital Employed (ROCE)	5.74%
Revenue Per Employee	453.81M
Profits Per Employee	131.47M
Employee Count	106
Asset Turnover	0.38
Inventory Turnover	3.03

Taxes

In the past 12 months, Cell Biotech has paid 334.93 million in taxes.

Income Tax	334.93M
Effective Tax Rate	2.35%

Stock Price Statistics

The stock price has increased by +6.05% in the last 52 weeks. The beta is 0.63, so Cell Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.63
52-Week Price Change	+6.05%
50-Day Moving Average	13,301.80
200-Day Moving Average	13,461.40
Relative Strength Index (RSI)	42.42
Average Volume (20 Days)	14,964

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cell Biotech had revenue of KRW 48.10 billion and earned 13.94 billion in profits. Earnings per share was 2,035.91.

Revenue	48.10B
Gross Profit	34.44B
Operating Income	7.09B
Pretax Income	14.27B
Net Income	13.94B
EBITDA	10.89B
EBIT	7.09B
Earnings Per Share (EPS)	2,035.91

Balance Sheet

The company has 89.29 billion in cash and 859.34 million in debt, giving a net cash position of 88.43 billion or 12,921.34 per share.

Cash & Cash Equivalents	89.29B
Total Debt	859.34M
Net Cash	88.43B
Net Cash Per Share	12,921.34
Equity (Book Value)	123.28B
Book Value Per Share	18,012.92
Working Capital	91.03B

Cash Flow

In the last 12 months, operating cash flow was 17.57 billion and capital expenditures -1.05 billion, giving a free cash flow of 16.52 billion.

Operating Cash Flow	17.57B
Capital Expenditures	-1.05B
Free Cash Flow	16.52B
FCF Per Share	2,414.23

Margins

Gross margin is 71.59%, with operating and profit margins of 14.73% and 28.97%.

Gross Margin	71.59%
Operating Margin	14.73%
Pretax Margin	29.67%
Profit Margin	28.97%
EBITDA Margin	22.64%
EBIT Margin	14.73%
FCF Margin	34.35%

Dividends & Yields

This stock pays an annual dividend of 450.00, which amounts to a dividend yield of 3.40%.

Dividend Per Share	450.00
Dividend Yield	3.40%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	22.10%
Buyback Yield	n/a
Shareholder Yield	3.40%
Earnings Yield	15.48%
FCF Yield	18.36%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Cell Biotech has an Altman Z-Score of 8.69 and a Piotroski F-Score of 6.

Altman Z-Score	8.69
Piotroski F-Score	6